Abstract:Therapeutic Advances in Drug Safety, Volume 14, Issue , January-December 2023. Aims:To investigate the safety of oral iron therapy in pregnant women with iron-deficiency anemia (IDA) in the real world.Methods:A retrospective analysis was performed on 1792 pregnant patients with IDA who received oral iron supplements from 12 hospitals in Shandong Province from 1 April to 31 June 2021; follow-up and adverse reactions were recorded. They were divided into six groups according to the treatment drugs.Results:The overall adverse reaction rate was 15.4%, and the main adverse reaction site was the digestive system. The incidence of all kinds of oral iron adverse reactions from high to low in order: compound ferrous sulfate and folic acid tablets (21.88%); iron proteinsuccinylate oral solution (20.90%); ferrous succinate tablets (19.76%); ferrous succinate sustained-release tablets (18.00%); iron polysaccharide complex capsule (12.06%); and iron dextran oral solution (6.94%). It was found that there was a significant difference in the incidence of adverse reactions among the six drugs (p < 0.05). Pairwise comparison showed that the incidence of adverse reactions was higher in the iron proteinsuccinylate oral solution than that in the iron polysaccharide complex capsule (p 0.05), but there was a significant difference in the incidence of adverse reactions in different gestational ages (p < 0.05). In Adverse Drug Reaction (ADR) patients, the adverse reaction result of most patients is recovery or improvement, and there was no serious adverse reaction outcome such as sequela and death.Conclusion:All the adverse reactions of oral iron were mainly gastrointestinal adverse reactions, and no heavy adverse reactions were found. Iron proteinsuccinylate oral solution has a higher incidence of adverse reactions than iron polysaccharide complex capsule. The results showed that oral iron was safer for anemia patients during pregnancy.Plain language summarySafety of oral iron in the treatment of iron-deficiency anemia during pregnancyIntroduction: The safety of different oral iron agents varies. At present, the safety evaluation of iron supplements in the treatment of anemia during pregnancy is mainly focused on intravenous iron supplements, and there is no comprehensive study on the safety of commonly used oral iron supplements. This study compared the safety of six commonly used oral iron supplements in the treatment of iron-deficiency anemia during pregnancy, aiming to provide a reference for clinical medication.Methods: We conducted a study involving 1792 patients in 12 hospitals in Shandong Province from 1 April to 31 June 2021.Results: Among the six groups, 276 ADR patients reported 302 adverse reactions. There were significant differences in the rates of adverse reactions among the six oral iron agents, and the incidence of adverse reactions in the iron proteinsuccinylate oral solution was significantly higher than that of iron polysaccharide complex capsules. The main incidence of adverse reactions was constipation (6.96%), and most of the outcomes were cured or improved.Conclusion: In this study, there were no heavy adverse reactions. The incidence of adverse reactions of iron proteinsuccinylate oral was higher than that of iron polysaccharide compound capsule. The results showed that oral iron had a good safety in patients with anemia during pregnancy.

Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy: A network meta-analysis

Clinical efficacy of polysaccharide iron complex plus vitamin C in the treatment of iron deficiency anemia in pregnancy and their effect on iron metabolism

Study on the changes of RBC, Hct, and Ret levels in patients with anemia during pregnancy and clinical treatment

Research Progress on the Clinical Treatment of Iron Deficiency Anemia in Pregnancy by Combining Chinese and Western Medicine

Comparative Evidence for Intrahepatic Cholestasis of Pregnancy Treatment with Traditional Chinese Medicine Therapy: A Network Meta-Analysis

A Randomized, Controlled, Open Label Non-Inferiority Trial of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Patients with Iron Deficiency Anemia in China.

Iron-containing Micronutrient Supplementation of Chinese Women with No or Mild Anemia During Pregnancy Improved Iron Status but Did Not Affect Perinatal Anemia.

The efficiency and safety of Shengxuening tablet on treating and preventing iron deficiency anemia: A systematic review and meta-analysis

Iron parameters in pregnant women with beta-thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supplementation in beta-thalassaemia minor during pregnancy

Cost-effectiveness analysis of parenteral iron therapy compared to oral iron supplements in managing iron deficiency anemia among pregnant women

Micronutrient Supplementation and Pregnancy Outcomes: Double-Blind Randomized Controlled Trial in China.

Micronutrient Supplementation During Pregnancy and the Risk of Pregnancy-Induced Hypertension: A Randomized Clinical Trial

Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study

Clinical effectiveness of ferric carboxymaltose (iv) versus iron sucrose (iv) in treatment of iron deficiency anaemia in pregnancy: A systematic review and meta-analysis

Prenatal Supplementations of Iron, Iron-Containing Multimicronutrients and Antianemic Chinese Patent Medicines in Women in Shaanxi Province, 2010-2013

Adverse effects of iron deficiency anemia on pregnancy outcome and offspring development and intervention of three iron supplements

Protective effect of Angelica sinensis polysaccharide on pregnant rats suffering from iron deficiency anemia via regulation of the hepcidin-FPN1 axis

Impact of Iron‐containing Micronutrient Supplementation on High Hemoglobin Concentration During Pregnancy

A double blind randomised controlled trial comparing standard dose of iron supplementation for pregnant women with two screen-and-treat approaches using hepcidin as a biomarker for ready and safe to receive iron

Prenatal Iron Containing Supplements Provided to Chinese Women with No or Mild Anemia Had No Effect on Hemoglobin Concentration in Post-Partum Women or Their Infants at 6 and 12 Months of Age

The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment